Anti-malignant tumor agent
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 14, 2017
Grant Date -
Jan 1, 2015
app pub date -
Jan 23, 2013
filing date -
Jan 23, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X. A substance targeting RPL29 and/or RPS4X is an anti-RPL29 antibody and/or anti-RPS4X antibody, a substance capable of activating or enhancing an endogenous anti-RPL29 antibody and/or anti-RPS4X antibody in a living body, a substance capable of inducing production of the anti-RPL29 antibody and/or anti-RPS4X antibody in a living body, or an antagonist of RPL29 and/or RPS4X. Furthermore, the present invention also extends to an examination method of malignant tumors which uses the anti-RPL29 and/or anti-RPS4X antibody titer as an indicator.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully